Lead sponsor
Janssen Research & Development, LLC
9 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
9
Trials led
0
Ongoing
3,549
Total enrollment
355
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Early Phase 1
1
Phase 1
2
Phase 2
4
Phase 2/3
1
Phase 3
1
Trials by status
Completed
5
Terminated
4
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's DiseaseAlzheimer's diseasePh 3Terminated2,051
A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Diseaseprodromal ADPh 2Completed114
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease SpectrumAge 50-85Ph 2Terminated90
A Study of Seltorexant in Participants With Probable Alzheimer's DiseaseAlzheimer's diseasePh 2Completed88
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's DiseaseAge 55-75Ph 1Completed72
A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's DiseaseAmyloid biomarker required (PET/CSF)Ph 1Completed45
Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)Age 50-85Early Ph 1Completed9